Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease ; volume:14 ; number:1 ; day:24 ; month:9 ; year:2022 ; pages:1-13 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (24.9.2022), 1-13, 12.2022

Creator: Rubinski, Anna
Franzmeier, Nicolai
Dewenter, Anna
Luan, Ying
Smith, Ruben
Strandberg, Olof
Ossenkoppele, Rik
Dichgans, Martin
Hansson, Oskar
Ewers, Michael

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-022-01074-9

URN: urn:nbn:de:101:1-2022121221100711562703

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Rubinski, Anna
Franzmeier, Nicolai
Dewenter, Anna
Luan, Ying
Smith, Ruben
Strandberg, Olof
Ossenkoppele, Rik
Dichgans, Martin
Hansson, Oskar
Ewers, Michael
SpringerLink (Online service)

Other Objects (12)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Related objects

Reset password